[Translation] Phase III, multicenter, randomized, double-blind, placebo-controlled, parallel-group study evaluating the efficacy, safety, and tolerability of Atogepant for the prevention of chronic migraine
评价atogepant 30 mg BID和atogepant 60 mg每日一次用于预防CM的安全性和耐受性。 前瞻性检验atogepant(30 mg BID和atogepant 60 mg每日一次)相较于安慰剂组用于预防CM的优效性。
[Translation] To evaluate the safety and tolerability of atogepant 30 mg BID and atogepant 60 mg once daily for the prevention of CM. The superiority of atogepant (30 mg BID and atogepant 60 mg once daily) compared with placebo for the prevention of CM was prospectively tested.